| Identification | More | [Name]
6-Aminoindole | [CAS]
5318-27-4 | [Synonyms]
1H-INDOL-6-AMINE
6-AMINO-1H-INDOLE
6-AMINOINDOLE
6-Indolamine
INDOLE-6-AMINE
indolin-6-amine
6-AMINOINDOLINE
6-AMINO-BENZOXAZOLE
2,3-Dihydro-1H-indol-6-amine | [EINECS(EC#)]
627-713-5 | [Molecular Formula]
C8H8N2 | [MDL Number]
MFCD02093959 | [Molecular Weight]
132.16 | [MOL File]
5318-27-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
75-79 °C | [Boiling point ]
161-166°C 2mm | [density ]
1.268±0.06 g/cm3(Predicted) | [Fp ]
161-166°C/2mm | [storage temp. ]
Keep Cold | [solubility ]
soluble in Methanol | [form ]
Crystalline Powder | [pka]
18.23±0.30(Predicted) | [color ]
White to brown | [Sensitive ]
Air Sensitive | [BRN ]
112190 | [CAS DataBase Reference]
5318-27-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [Hazard Note ]
Harmful | [HazardClass ]
IRRITANT-HARMFUL, KEEP COLD | [PackingGroup ]
III | [HS Code ]
29339900 |
| Hazard Information | Back Directory | [Chemical Properties]
Solid | [Uses]
Reactant for preparation of:
- Inhibitors of mammalian target of rapamycin (mTOR ) protein
- Inhibitors of the AcrAB-TolC efflux pump
- Inhibitors of Gli1-mediated transcription in the Hedgehog pathway
- Potent DNA-topoisomerase II poisons and anti-MDR agents
- Protein kinase C θ (PKCθ) inhibitors
- Piperidine carboxamide as transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists
- Potent and selective blockers of the Nav1.8 sodium channel as potential analgesics for the treatment of neuropathic and inflammatory pain
- 5,6-fused heteroaromatic ureas as TRPV1 antagonists
- Allosteric enhancers of the A3 adenosine receptor
- Human liver glycogen phosphorylase (HLGP) inhibitors for the treatment of type 2 diabetes
|
|
|